logo
Book a meeting
AlphaVax

Alpha Vax

Biotechnology, 2 Triangle Dr, Research Triangle Park, North Carolina, 27709, United States, 51-200 Employees

alphavax.com

  • LinkedIn

phone no Phone Number: 19*********

Who is ALPHAVAX

The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biode...

Read More

lock icon Get Full Access
map
  • 2 Triangle Dr, Research Triangle Park, North Carolina, 27709, United States Headquarters: 2 Triangle Dr, Research Triangle Park, North Carolina, 27709, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • Peter Young CEO:   Peter Young

industries-icon Industry: Biotechnology

SIC SIC Code: 8011 | NAICS Code: 621991 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ALPHAVAX

AlphaVax Org Chart and Mapping

Peter Young

Peter Young

CEO

See Full Org Chart arrow
email-formate-icon
View Email Formats for AlphaVax
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding AlphaVax

Answer: AlphaVax's headquarters are located at 2 Triangle Dr, Research Triangle Park, North Carolina, 27709, United States

Answer: AlphaVax's phone number is 19*********

Answer: AlphaVax's official website is https://alphavax.com

Answer: AlphaVax's revenue is $10 Million to $25 Million

Answer: AlphaVax's SIC: 8011

Answer: AlphaVax's NAICS: 621991

Answer: AlphaVax has 51-200 employees

Answer: AlphaVax is in Biotechnology

Answer: AlphaVax contact info: Phone number: 19********* Website: https://alphavax.com

Answer: The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access